接受非维生素K拮抗剂口服抗凝药患者的围手术期管理:最新推荐
本文是一篇综述,汇总近期临床证据、专家共识及NOAC可预测的药理学特性,提出接受NOAC(达比加群、利伐沙班、阿哌沙班、依度沙班)患者围手术期多学科管理策略。择期高出血风险手术停NOAC 2天即可,椎管内麻醉需停3天;达比加群需根据肾功能额外停1–2天。NOAC不需术前肝素桥接。急诊/紧急手术应尽量延迟至少12小时(>24小时更佳),不能延迟时考虑特异性逆转剂(达比加群用idarucizumab,利伐沙班/阿哌沙班/依度沙班用andexanet alfa),不可及时用凝血酶原复合物浓缩物。
要点
- 择期高出血风险手术:停NOAC 2天即可,无论NOAC类型;椎管内麻醉需停3天。
- 达比加群在以上基础上需按肾功能下降额外停1–2天。
- NOAC术前不需要肝素桥接治疗。
- 急诊/紧急手术应尽量延迟至少12小时(>24小时更佳);不能延迟时考虑特异性逆转剂。
- 特异性逆转剂:达比加群用idarucizumab;利伐沙班、阿哌沙班、依度沙班用andexanet alfa;不可及时用凝血酶原复合物浓缩物。
适用人群与场景
- 接受NOAC(达比加群、利伐沙班、阿哌沙班、依度沙班)并拟行择期、椎管内麻醉或急诊/紧急手术的患者。
诊断标准与关键阈值
- 原文未提及
处置流程与药物剂量
- 择期高出血风险手术:停NOAC 2天(无论NOAC类型)。
- 椎管内麻醉:停NOAC 3天。
- 达比加群:在上述停药时间基础上,根据肾功能下降额外停1–2天。
- NOAC术前不需要肝素桥接治疗。
- 急诊/紧急手术:尽量延迟至少12小时(>24小时更佳);不能延迟时考虑特异性逆转剂。
- 特异性逆转剂:达比加群用idarucizumab;利伐沙班、阿哌沙班、依度沙班用andexanet alfa;不可及时用凝血酶原复合物浓缩物。
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- (本栏提炼含原文里核对不到的数值,已删除,请以原文为准)
证据类型、等级与局限
- 证据类型:综述;证据等级或推荐强度:原文未提及;局限:原文指出相关临床证据匮乏,推荐基于新兴临床证据、专家共识及NOAC可预测的药理学特性。
对床旁实践的改变
- 择期高出血风险手术停NOAC 2天、椎管内麻醉停3天,达比加群按肾功能额外停1–2天,无需肝素桥接。
- 急诊/紧急手术尽量延迟至少12小时(>24小时更佳),不能延迟时使用特异性逆转剂或凝血酶原复合物浓缩物。
- 原文未提及适用与不适用人群的进一步区分及常见陷阱。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Indications of non-vitamin K antagonist oral anticoagulants (NOACs), consisting of two types: direct thrombin inhibitor (dabigatran) and direct factor Xa inhibitor (rivaroxaban, apixaban, and edoxaban), have expanded over the last few years. Accordingly, increasing number of patients presenting for surgery are being exposed to NOACs, despite the fact that NOACs are inevitably related to increased perioperative bleeding risk. This review article contains recent clinical evidence-based up-to-date recommendations to help set up a multidisciplinary management strategy to provide a safe perioperative milieu for patients receiving NOACs. In brief, despite the paucity of related clinical evidence, several key recommendations can be drawn based on the emerging clinical evidence, expert consensus, and predictable pharmacological properties of NOACs. In elective surgeries, it seems safe to perform high-bleeding risk surgeries 2 days after cessation of NOAC, regardless of the type of NOAC. Neuraxial anesthesia should be performed 3 days after cessation of NOACs. In both instances, dabigatran needs to be discontinued for an additional 1 or 2 days, depending on the decrease in renal function. NOACs do not require a preoperative heparin bridge therapy. Emergent or urgent surgeries should preferably be delayed for at least 12 h from the last NOAC intake (better if > 24 h). If surgery cannot be delayed, consider using specific reversal agents, which are idarucizumab for dabigatran and andexanet alfa for rivaroxaban, apixaban, and edoxaban. If these specific reversal agents are not available, consider using prothrombin complex concentrates.
参考来源
- Kim KS, Song JW, Soh S, et al. Perioperative management of patients receiving non-vitamin K antagonist oral anticoagulants: up-to-date recommendations. Anesth Pain Med (Seoul). 2020. PMID: 33329805. doi:10.17085/apm.2020.15.2.133
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。